Allena Pharmaceuticals, Inc. EPS (Basic, Consolidated)

EPS (Basic, Consolidated) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including EPS (Basic, Consolidated) growth rates and interactive chart.


Highlights and Quick Summary

  • EPS (Basic, Consolidated) for the quarter ending March 31, 2022 was -0.13 (a 35.04% increase compared to previous quarter)
  • Year-over-year quarterly EPS (Basic, Consolidated) decreased by -45.19%
  • Annual EPS (Basic, Consolidated) for 2021 was -0.72 (a -29.13% decrease from previous year)
  • Annual EPS (Basic, Consolidated) for 2020 was -1.01 (a -52.66% decrease from previous year)
  • Annual EPS (Basic, Consolidated) for 2019 was -2.13 (a 24.18% increase from previous year)
  • Twelve month EPS (Basic, Consolidated) ending March 31, 2022 was -0.64 (a -11.07% decrease compared to previous quarter)
  • Twelve month trailing EPS (Basic, Consolidated) decreased by -28.99% year-over-year
Trailing EPS (Basic, Consolidated) for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-0.64 -0.72 -0.84 -0.9
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EPS (Basic, Consolidated) of Allena Pharmaceuticals, Inc.

Most recent EPS (Basic, Consolidated)of ALNA including historical data for past 10 years.

Interactive Chart of EPS (Basic, Consolidated) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. EPS (Basic, Consolidated) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -0.13
2021 -0.1 -0.17 -0.24 -0.21 -0.72
2020 -0.22 -0.22 -0.26 -0.31 -1.01
2019 -0.48 -0.57 -0.54 -0.55 -2.13
2018 -0.46 -0.46 -0.42 -0.38 -1.72
2017 6.36 -3.48 -3.45 -4.22 -4.79
2016 -4.57 -18.3
2015 -11.33

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.